Research – Rutgers Institute for Information Policy and Law (RIIPL)

Professor Ellen P. Goodman

Goodman Scholarship

The effect of traffic light veracity labels on perceptions of political advertising source and message credibility on social media, Journal of Information Technology & Politics (2023) (with Tom Dobber, Sanne Kruikemeier, Fabio Votta, & Natali Helberger)
Exploring Police Perspectives on Algorithmic Transparency: A Qualitative Analysis of Police Interviews in the UK, EAAMO ’23: Proceedings of the ACM Conference on Equity and Access in Algorithms, Mechanisms, and Optimization 2023, Article 25, 1–19 (with Miri Zilka, Carolyn Ashurst, Luke Chambers, Pamela Ugwudike, & Marion Oswald)
Algorithmic Auditing: Chasing Accountability, 39 Santa Clara High Tech. L. J. 289 (2023) (with Julia Trehu)
The Impact of Twitter Labels on Misinformation Spread and User Engagement: Lessons from Trump’s Election Tweets, WWW ’22: Proceedings of the ACM Web Conference 2022, 2541–2551 (with Orestis Papakyriakopoulos)
AI Audit Washing and Accountability, GMF (2022) (with Julia Trehu)
Information Fidelity and Friction, 21 Nev. L. Rev. 623 (2021)
Creating a Covid-19 Commission on Public Health Misinformation (with Blair Levin), Day One Project (2021)
A “Full Stack” Approach to Public Media in the US (with Sanjay Jolly), GMF (2021)
The Stakes of User Interface Design for Democracy (with Karen Kornbluh), GMF (2021)
Safeguarding Democracy Against Disinformation: Digital Innovation and Democracy Initiative Roadmap (with Karen Kornbluh), German Marshall Fund (2020)
Digital Information Fidelity and Friction, Knight-Columbia First Amendment paper (2020)
Smart City Ethics: How “Smart” Challenges Democratic Governance, in Oxford Handbook of the Ethics of Artificial Intelligence (Ed. by Markus D. Dubber et al.) (Oxford University Press 2020)
Report of the Media Subcommittee for the Study of Digital Platforms, George J. Stigler Center for the Study of the Economy and the State The University of Chicago Booth School of Business (July 2019) (co-author)
Section 230 of the Communications Decency Act and the Future of Online Speech (with Ryan Whittington), German Marshall Fund (Aug. 2019)
Urbanism Under Google: Lessons from Sidewalk Toronto, 88 Fordham L. Rev. 457 (2019) (with Julia Powles)
The First Amendment Opportunism of Digital Platforms, German Marshall Fund (2019)
Defining Equity in Algorithmic Change, Regulatory Review (2019)
Algorithmic Transparency for Smart Cities, 20 Yale J. of Law & Tech. 103 (2018) (with Robert Brauneis)
Four Ages of Public Media, American Academy of Arts and Sciences (2017)
Zero Rating and Equity at the Network’s Other Edge 15 Colo. Tech. L. J. 63 (2016)
Atomic Age of Data: Policies for the Internet of Things, Aspen Institute Report (2015)
Anchor Institutions and Broadband Justice, 41 Fordham Urban L. J. 1665 (2014)
Visual Gut Punch: Persuasion, Emotion, and the Constitutional Meaning of Graphic Disclosure, 99 CORNELL L. REV. 513 (2014)
Modeling Policy for Public Media, 24 HARV. J. OF LAW & TECH. 112 (2010) (with Anne H. Chen)
Digital Public Service Media Networks to Advance Broadband and Enrich Connected Communities, 9 J.TELECOM & HIGH TECH. L. 82 (2010) (with Anne H. Chen)
Spectrum Auctions and the Public Interest, 7 J. TELECOM & HIGH TECH. L. 343(2009)
No Time for Equal Time, 76 GEO. WASH. L. REV.897 (2008) (symposium issue)
Free Speech and Media Policy: The First Amendment at War With Itself, 35 HOFSTRA L. REV. 1211 (2007) (symposium issue)
Peer Promotions and False Advertising Law, 58 S. CAR. L. REV. 683 (2007) (symposium issue)
Stealth Marketing and Editorial Integrity, 85 TEX. L. REV. 83 (2006)
Spectrum Equity, 41 J. TELECOM. & HIGH TECH. L. 101(2005)
Media Policy Out of the Box: Content Abundance, Attention Scarcity, and the Failures of Digital Markets, 19 BERKELEY TECH. L. J. 1389 (2004)
Spectrum Rights in the Telecosm to Come, 41 SAN DIEGO L. REV. 269 (2004)
Public Media Policy Reform and Digital Age Realities in Communications Law and Policy in the Digital Age: The Next Five Years (Randolph May ed.) (Carolina Academic 2012)
Public Service Media Narratives in Handbook of Media Law and Policy: A Socio-Legal Exploration (Monroe E. Price & Stefaan G. Verhulst, ed.)(Routledge 2012)
FCC, Information Needs of Communities (2011) (principal author of 50 page nonprofit media section)
Spectrum Policy and the Public Interest in Television Goes Digital (Darcy Gerbarg ed., 2009)
Public Service Media 2.0 in … And Communications for All: A Policy Agenda for a New Administration (Amit M. Schejter ed., 2009)
Public Television and Pluralistic Ideals in The Future of Public Service Broadcasting (Tim Gardam & David Levy ed., 2008)
Spectrum Sharing and Spectrum Efficiency in A Framework for a National Broadband Policy (Aspen Institute 2008)
Proactive Media Policy in an Age of Content Abundance in Media Diversity and Localism: Meanings and Metrics (Philip M. Napoli ed., 2006)
Tender Justice: Judge Shapiro’s Hard-Headed Humanity, 152 U. PA. L. REV. 25 (2003)
Bargains in the Information Marketplace: The Use of Government Subsidies to Regulate New Media, 1 J. TELECOM. & HIGH TECH. L. 217 (2002)
Digital Television and the Allure of Auctions: The Birth and Stillbirth of DTV Legislation, 49 FED. COMM. L.J. 517 (1997)

Goodman Public Communication

Three Steps to Help Treat America’s Debilitating Information Disorder (with Karen Kornbluh), Washington Post (1/21)
San Diego, Street Smarts and Surveillance (with Kayvon Paul), Protego Press (11/20)
How Did Twitter, Facebook, and YouTube Handle Misinformation During the Election? (with Karen Kornbluh), Slate (11/20)
Social Media Platforms Need to Flatten the Curve of Dangerous Misinformation, (with Karen Kornbluh), Slate (8/20)
Sidewalk Toronto Goes Sideways: Five Lessons for Digital Governance, Protego Press (6/20)
Ignore Trump’s Twitter Tantrum Executive Order and Address Disinformation Instead (with Karen Kornbluh), Just Security (6/20)
The Real Free Speech Problem on Social Media, (with Karen Kornbluh), Slate (6/20)
Dueling Platform Policies and Free Speech Online, Constitution Center We The People Podcast (Nov. 2019)
Facebook, Free Speech, and Political Advertising, WHYY Radio Times Podcast, (Nov. 2019)
The More Outrageous the Lie, the Better it is for Facebook’s Bottom Line, The Los Angeles Times (Nov. 2019) (with Karen Kornbluh)
How Facebook Shot Themselves in the Foot in their Elizabeth Warren Spat, The Guardian (Oct. 2019) (with Karen Kornbluh)
How to Regulate the Internet(with Karen Kornbluh), Project Syndicate (7/10/19)
Bringing Truth to the Internet, Democracy Journal (Summer 2019, No. 53) (with Karen Kornbluh)
Curb its Enthusiasm: As Sidewalk Labs Moves Fast in Toronto, Pay Attention to the Streets, The Globe and Mail (6/4/19)
Reviving the Personal Attack Rule for Digital Platforms is Not a Good Idea, Protego Press (5/28/19)
Facebook’s Moment for Thought Leadership on Internet Regulation Has Passed, Protego Press (4/2/19)
So Mark Zuckerberg Wants to Repent for Facebook’s Sins? He Can Start Here, The Guardian (Oct. 2017)
Facebook Should Consider Subsidizing and Promoting Local News, Slate (Dec. 2016)
Facebook and Google: Most Powerful and Secretive Empires We’ve Ever Known, The Guardian (Sept. 2016) (with Julia Powles)
Self-Driving Cars: Overlooking Data Privacy is a Crash Waiting to Happen, The Guardian (June 2016)
Big Pharma, Tobacco, Tech., – How the First Amendment is Being Abused, The Guardian (Mar. 2016)
India’s Ban on Facebook’s Free Service is an Overreaction, The Guardian (Feb. 2016)

Professor Michael Carrier

Pharmaceutical Antitrust Enforcement in the United States and Chile (with Fernando Araya), 8 Journal of Law and the Biosciences 1 (2021)
Rescuing Antitrust’s Role in Patent Holdup, 168 University of Pennsylvania Law Review Online 238 (2021)
Don’t Die! How Biosimilar Disparagement Violates Antitrust Law, 115 Northwestern University Law Review Online 119 (2020)
Pay-for-Delay: Who Does the Generic Industry Lobby Represent?, CPI Antitrust Chronicle (May 2020)
Playing Both Sides? Branded Sales, Generic Drugs, and Merger Policy (with Mark A. Lemley & Shawn Miller), 71 Hastings Law Journal 307 (2020)
Three Challenges for Pharmaceutical Antitrust, 59 Santa Clara Law Review 613 (2020) (symposium)
Big Tech, Antitrust, and Breakup, Georgetown Journal of International Affairs (January 2020)
Why Absolutist Conceptions of Property Do Not Support the Antitrust Abandonment of Standards, 57 Houston Law Review 265 (2019) (symposium)
Higher Drug Prices from Anticompetitive Conduct: Three Case Studies, 39 The Journal of Legal Medicine 151 (2019) (symposium)
Why the NCAA’s No-Transfer Rule Is No Good (with Marc Edelman), The University of Chicago Law Review Online (2019)
College Athletics: The Chink in the Seventh Circuit’s “Law and Economics” Armor (with Marc Edelman), 117 Michigan Law Review Online 90 (2019)
Don’t Ditch Antitrust’s Role in Product Hopping: A Response to Pace and Adam (with Steve D. Shadowen), 33 ANTITRUST 72 (2019)
The Four-Step Rule of Reason, 33 ANTITRUST 50 (2019)
A Non-Coercive Approach to Product Hopping (with Steve D. Shadowen), 33 ANTITRUST 102 (2018)
Antitrust, Market Exclusivity, and Transparency in the Pharmaceutical Industry (with Michael S. Sinha and Greg D. Curfman, 319 JAMA 2271 (2018)
Biologics: The New Antitrust Frontier (with Carl J. Minniti III), 2018 University of Illinois Law Review 1 (2018)
Five Actions to Stop Citizen Petition Abuse, 118 Columbia Law Review Online 81 (2018)
The Curious Case of Wellbutrin: How the Third Circuit Mistook Itself for the Supreme Court, 103 Cornell Law Review Online 137 (2018)
William Howard Taft Lecture: The Rule of Reason in the Post-Actavis World, 2018 Columbia Business Law Review 26 (2018)
Sharing, Samples, and Generics: An Antitrust Framework, 103 Cornell Law Review 1 (2017)
Five Solutions to the REMS Patent Problem (with Brenna Sooy), 97 Boston University Law Review 1661 (2017)
Using Antitrust Law to Challenge Turing’s Daraprim Price Increase (with Nicole Levidow and Aaron S. Kesselheim), 31 Berkeley Technology Law Journal 1379 (2017)
The Untold EpiPen Story: How Mylan Hiked Prices by Blocking Rivals (with Carl J. Minniti III), 102 Cornell Law Review Online 53 (2017)
Citizen Petitions: Long, Late-Filed, and At-Last Denied (with Carl J. Minniti III), 66 American University Law Review 305 (2016)
Product Hopping: A New Framework (with Steve Shadowen), 92 Notre Dame Law Review 167 (2016)
Pharmaceutical Antitrust: What the Trump Administration Can Do, Concurrences: Competition Law Review 63 (No. 4, 2016)
Pleading Standards: The Hidden Threat to Actavis, 91 N.Y.U. L. Rev. Online 31 (2016)
Why “Large and Unjustified Payment” Is Not a Threshold Under Actavis, 91 Washington Law Review 109 (2016) (symposium)
Strategies that Delay or Prevent the Timely Availability of Affordable Generic Drugs in the United States (with Gregory H. Jones, Richard T. Silver, & Hagop Kantarjian), 127 Blood (journal published by the American Society of Hematology) 1398 (2016)
The “Equity of the Statute” and Copyright Law: Three Critiques, 163 U. Pa. L. Rev. Online 377 (2015) (response to Shyamkrishna Balganesh & Gideon Parchomovsky, Equity’s Unstated Domain: The Role of Equity in Shaping Copyright Law, 163 U. Pa. L. Rev. 1859 (2015)
How Not to Apply the Rule of Reason: The O’Bannon Case, 114 Michigan Law Review First Impressions 73 (2015)
Eight Reasons Why “No-Authorized-Generic” Promises Constitute Payment, 67 Rutgers University Law Review 697 (2015) (symposium)
After Actavis: Seven Ways Forward, 67 Rutgers University Law Review 543 (2015) (symposium)
O’Bannon v. National Collegiate Athletic Association: Why the Ninth Circuit Should Not Block the Floodgates of Change in College Athletics (with Chris Sagers) (response to Marc Edelman, The District Court Decision in O’Bannon v. National Collegiate Athletic Association: A Small Step Forward for College-Athletes, and a Gateway for Far Grander Change, 71 Washington and Lee Law Review Online 299 (2015)) (symposium)
How Not To Apply Actavis, 109 Northwestern University Law Review Online 113 (2015)
No, RIAA, It’s Not the End of the World for Musicians, 83 UMKC Law Review 287 (2014) (symposium)
Payment After Actavis, 100 Iowa Law Review 7 (2014)
Pharmaceutical Antitrust Complexity, Competition Policy International (Vol. 10, No. 2, 2014) (symposium)
What You Need to Know About Standard Essential Patents, Competition Policy International (Vol. 8, No. 2, 2014)
Limelight v. Akamai: Limiting Induced Infringement, 2014 Wisconsin Law Review online 1
Only “Scraping” the Surface: The Copyright Hole in the FTC’s Google Settlement, 46 University of British Columbia Law Review 759 (2014) (symposium)
A Response to Chief Justice Roberts: Why Antitrust Must Play A Role in the Analysis of Drug Patent Settlements, 15 Minnesota Journal of Law, Science & Technology 31 (2014) (symposium)
Five Arguments Laid to Rest After Actavis, 13 Antitrust Source 1 (2013)
Google and Antitrust: Five Approaches to an Evolving Issue, Harvard Journal of Law and Technology Occasional Paper Series (July 2013)
Copyright and Innovation: Responses to Marks, Masnick, and Picker, 2013 Wisconsin Law Review Online 46
Increasing Innovation Through Copyright Common Sense and Better Government Policy, 62 Emory Law Journal 983 (2013) (symposium)
Patent Assertion Entities: Six Actions the Antitrust Agencies Can Take, Competition Policy International: Antitrust Chronicle (Vol. 1 No. 2, 2013)
SOPA, PIPA, ACTA, TPP: An Alphabet Soup of Innovation-Stifling Copyright Legislation and Agreements, 11 Northwestern Journal of Technology and Intellectual Property 21 (2013) (symposium)
Citizen Petitions: An Empirical Study (with D. Wander), 34 Cardozo Law Review 249 (2012)
Why the “Scope of the Patent” Test Cannot Solve the Drug Settlement Problem, 16 Stanford Technology Law Review 1 (2012)
A Roadmap to the Smartphone Patent Wars and FRAND Licensing, Competition Policy International: Antitrust Chronicle (Vol. 4 No. 2, 2012) (solicited)
A Tort-Based Causation Framework for Antitrust Analysis, 77 Antitrust Law Journal 991 (2011) (symposium)
Post-Grant Opposition: A Proposal and a Comparison to the America Invents Act, 45 U.C. Davis Law Review 103 (2011)
An Antitrust Framework for Climate Change, 9 Northwestern Journal of Technology and Intellectual Property 513 (2011)
A Real-World Analysis of Pharmaceutical Settlements: The Missing Dimension of Product-Hopping, 62 Florida Law Review 1009 (2010)
Innovation for the 21st Century: A Response to Seven Critics, 61 Alabama Law Review 597 (2010) (symposium)
Solving the Drug Settlement Problem: The Legislative Approach, 40 Rutgers Law Journal 83 (2010) (symposium)
The Pirate Bay, Grokster, and Google, 15 Journal of Intellectual Property Rights 7 (2010) (solicited)
Unsettling Drug Patent Settlements: A Framework for Presumptive Illegality, 108 Michigan Law Review 37 (2009)
The Rule of Reason in the 21st Century, 16 George Mason Law Review 827 (2009) (symposium)
Two Puzzles Resolved: Of the Schumpeter-Arrow Stalemate and Pharmaceutical Innovation Markets, 93 Iowa Law Review 393 (2008)
Why Modularity Does Not (and Should Not) Explain Intellectual Property, 116 Yale Law Journal Pocket Part 95 (2007) (solicited),
Against Cyberproperty, 22 Berkeley Technology Law Journal 1485 (2007) (with Greg Lastowka)
Pictures at the New Economy Exhibition: Why the Antitrust Modernization Commission Got it (Mostly) Right, 38 Rutgers Law Journal 473 (2007) (symposium)
Of Trinko, Tea Leaves, and Intellectual Property, 31 Journal of Corporation Law 357 (2006) (symposium)
Vote Counting, Technology, and Unintended Consequences, 79 St. John’s Law Review 645 (2005)
Cabining Intellectual Property Through a Property Paradigm, 54 Duke Law Journal 1 (2004)
Resolving the Patent-Antitrust Paradox Through Tripartite Innovation, 56 Vanderbilt Law Review 1047 (2003)
Why Antitrust Should Defer to the Intellectual Property Rules of Standard Setting Organizations: A Commentary on Teece & Sherry, 87 Minnesota Law Review 2019 (2003)
Antitrust After the Interception: Of a Heroic Returner and Myriad Paths, 55 Stanford Law Review 287 (2002) [Review of Richard Posner, Antitrust Law (2d ed. 2001)]
Unraveling the Patent-Antitrust Paradox, 150 University of Pennsylvania Law Review 761 (2002)
The Real Rule of Reason: Bridging the Disconnect, 1999 Brigham Young University Law Review 1265 (1999)

Testimony

REMS Patents Should Not Be Listed in Orange Book, July 2020 comments on proposed FDA regulations on Listing of Patent Information in the Orange Book
Response to Representative Schakowsky’s Questions for the Record for House Energy & Commerce Committee (Subcommittee on Consumer Protection and Commerce) Hearing on “Profits Over Consumers: Exposing How Pharmaceutical Companies Game the System,” Oct. 22, 2019
Testimony for House Energy & Commerce Committee (Consumer Protection and Commerce Subcommittee) Hearing on “Profits over Consumers: Exposing how Pharmaceutical Companies Game the System,” Sept. 19, 2019
Responses to Questions for the Record by Senator Grassley, Senator Klobuchar, and Senator Blumenthal, May 2019
Testimony for Senate Judiciary Committee Hearing on “Intellectual Property and the Price of Prescription Drugs: Balancing Innovation and Competition,” May 2019
Testimony for House Energy & Commerce Committee (Health Subcommittee) Hearing on “Lowering the Cost of Prescription Drugs: Reducing Barriers to Market Competition,” March 2019
Addressing Abusive Citizen Petitions, October 2018 comments on proposed FDA regulations on Citizen Petitions and Petitions for Stay of Action Subject to Section 505(q) of the Federal Food, Drug, and Cosmetic Act
Five Proposals to Stop the Games and Encourage a Robust Biosimilar Market, September 2018 comments on “Facilitating Competition and Innovation in the Biological Products Marketplace; Public Hearing; Request for Comments,” FDA
IP and Competition: Context, Test, and Balance, comments on The role of intellectual property and competition policy in promoting innovation, FTC hearings on Competition and Consumer Protection in the 21^st Century
Essential Changes to Shared REMS, July 2018 comments to proposed FDA regulations:
Guidance for Industry Waivers of the Single, Shared System REMS Requirement and
Draft Guidance for Industry Development of a Shared System REMS
High Prices & No Excuses: 6 Anticompetitive Games, Federal Trade Commission workshop on “Understanding Competition in Prescription Drug Markets,” November 2017
Statement on “Antitrust Concerns and the FDA Approval Process,” Subcommittee on Regulatory Reform, Commercial and Antitrust Law, U.S. House Committee on the Judiciary, July 2017
Four Proposals to Enhance Generic Competition, U.S. Food and Drug Administration (FDA) hearing on “The Hatch-Waxman Amendments: Ensuring a Balance between Innovation and Access,” July 2017
Comments on Proposed Update on Intellectual Property Licensing Guidelines, U.S. Department of Justice Antitrust Division and Federal Trade Commission, August 2016
Eliminate Statutory Damages for Secondary Infringers, Department of Commerce Internet Policy Task Force Comment, January 2014
Statement on “Pay-for-Delay Deals: Limiting Competition and Costing Consumers,” Senate Judiciary Committee, Subcommittee on Antitrust, Competition Policy and Consumer Rights, July 2013
Antitrust Enforcement and Trolls, Federal Trade Commission and U.S. Department of Justice, Patent Assertion Entity Activities Workshop, December 2012
IP Enforcement Can’t Whack Every Mole but Can Stifle Technological Innovation,
U.S. Intellectual Property Enforcement Coordinator, Development of the Joint Strategic Plan on Intellectual Property Enforcement, August 2012
An Important, but Incomplete, Notice of Inquiry on Copyright and Innovation, National Telecommunications and Information Administration Inquiry on Copyright Policy, Creativity, and Innovation in the Internet Economy Docket # 100910448-0448-01, November 2010,
Innovation and Copyright: The Neglected Relationship, and Supplemental Remarks on Innovation/Copyright Hearings, Board on Science, Technology, and Economic Policy, The Impact of Copyright Policy on Innovation in the Digital Era, October 2010